Abstract
The sensitivity of drugs to one or more elements of the primary packaging is a serious concern for the pharmaceutical industry. Biologics in particular are highly sensitive, leading to a higher risk of incompatibility and stability test failures as worst case scenario. This potential incompatibility - and the consequent formulation instability due to the interactions between the drug and the primary container surface - may have multiple causes: the intrinsic nature of the container surface, leachables coming from the materials used, substances coming from the production process, silicone oil droplets or other particles. The Alba primary packaging platform was designed in order to have the same interface between the drug and the glass container surface on the different primary packaging containers to minimize the emergence of instabilities at later stages during the formulation development. The Alba containers are internally treated with an innovative cross-linked coating based on silicone oil lubricant and the additional rubber components have been selected to minimize the possible differences between the container typologies. This paper shows in deep details the subvisible particle release reduction and the comparability of the performances of different containers, obtained using such technology. To demonstrate this improvement, different analytical methods for particle measurement were used on bulk containers, Alba treated ones and containers from a standard production (spray-on siliconization). Considering that Alba containers are conform to the standard compendial testing and the amount of particles released from Alba coated syringes resulted comparable to the bulk ones for the first two mildly stressful methods, it was decided to develop and apply a more challenging method, such as an autoclave treatment for 1 hour at 121°C, to better highlight the performances of this innovative technology. The data obtained, under the most stressful conditions, shows a substantial reduction in the released particle concentrations compared to a spray-on siliconized container, and comparable performances for all the containers included in the Alba platform. The latter could heavily reduce the drug formulation development timings, facilitating the transition from a container to another.
- Primary Packaging
- Protein Aggregation
- Protein Formulation
- Silicone Oil
- Sub-Visible Particles
- Visible Particles
- Received January 29, 2018.
- Accepted April 12, 2018.
- Copyright © 2018, Parenteral Drug Association
PDA members receive access to all articles published in the current year and previous volume year. Institutional subscribers received access to all content. Log in below to receive access to this article if you are either of these.
If you are neither or you are a PDA member trying to access an article outside of your membership license, then you must purchase access to this article (below). If you do not have a username or password for JPST, you will be required to create an account prior to purchasing.
Full issue PDFs are for PDA members only.
Note to pda.org users
The PDA and PDA bookstore websites (www.pda.org and www.pda.org/bookstore) are separate websites from the PDA JPST website. When you first join PDA, your initial UserID and Password are sent to HighWirePress to create your PDA JPST account. Subsequent UserrID and Password changes required at the PDA websites will not pass on to PDA JPST and vice versa. If you forget your PDA JPST UserID and/or Password, you can request help to retrieve UserID and reset Password below.
